Exploring new therapeutic strategies in Hutchinson-Gilford progeria syndrome preclinical models

• Applicant: Professorin Dr. Karima Djabali
• Subject Area: Pediatric and Adolescent Medicine
• Term: from 2018 to 2022
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 398640205

• Final Report Year: 2022

No abstract available

Publications

• Inhibition of JAK-STAT Signaling with Baricitinib Reduces Inflammation and Improves Cellular Homeostasis in Progeria Cells. Cells, 8(10), 1276.
  Liu, Chang; Arnold, Rouven; Henriques, Gonçalo & Djabali, Karima
  
• Baricitinib, a JAK-STAT Inhibitor, Reduces the Cellular Toxicity of the Farnesyltransferase Inhibitor Lonafarnib in Progeria Cells. International Journal of Molecular Sciences, 22(14), 7474.
  Arnold, Rouven; Vehns, Elena; Randl, Hannah & Djabali, Karima
  
• Impact of Progerin Expression on Adipogenesis in Hutchinson—Gilford Progeria Skin-Derived Precursor Cells. Cells, 10(7), 1598.
  Najdi, Farah; Krüger, Peter & Djabali, Karima